
A medical device manufacturer selling into Europe and the United States is now audited against a quality system standard that both jurisdictions recognise. Since 2[…]

Auditing your pharmacovigilance system is not optional and not a quality-department formality. It is a legal obligation on the marketing authorisation holder, its results are[…]

Most regulated companies now run at least one GxP-critical process on software they do not host, cannot inspect directly, and cannot stop from updating. That[…]

Data integrity findings rarely arise because a company set out to falsify anything. They arise because nobody was looking. A system generates an audit trail,[…]

For two decades, validating software used in production and quality systems meant generating documentation — often a great deal of it, and often with little[…]

Almost every GxP decision a company makes today rests on data produced, stored or transformed by a computerised system. Regulators have responded by treating those[…]

A generic marketing authorisation application rests on a single scientific bridge: proof that your product behaves in the body the way the reference product does.[…]

Almost every pharmaceutical company outsources something — a manufacturing step, analytical testing, storage, transport, calibration, a hosted computerised system. What no company can outsource is[…]

Greece’s low reference prices make it an attractive place to buy medicines and a difficult place to keep them. EOF’s response is a rolling export[…]

Between a European approval and a Greek reimbursement decision there is typically more than a year. Greece has a defined early access framework to bridge[…]